EDAP TMS S.A. Confirms Strong 2004 Revenue Performance
January 14 2005 - 8:30AM
PR Newswire (US)
EDAP TMS S.A. Confirms Strong 2004 Revenue Performance - HIFU with
ABLATHERM(R) Business Taking Off - LYON, France, Jan. 14
/PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), ahead of the
release of its 2004 annual results scheduled for mid-March 2005,
today confirms strong sales revenue growth and steady cash position
for the full year of 2004. The Company's expectations for the full
year of 2004 are based on an over 20% increase in sales revenue,
strengthened gross margins and significant expense reductions
versus year 2003, aiming at positive operating income in both
divisions. This progression over year 2004 includes a dramatic
approximate 140% increase in Ablatherm(R) (devices and mobile
business) sales which confirms the growing interest for HIFU for
the treatment of localized prostate cancer. EDAP clinical and
technological leadership in HIFU, with more that 6,000 treatments
performed so far, strengthens its credibility and therefore
reinforces this high growth business trend. The Lithotripsy
activity today definitely provides momentum for the overall Group
business as it ensures a regular and steady business with
predictable high margins and significant recurring service
revenues. The Lithotripsy business was maintained over year 2004 on
a very mature market, despite the strengthening of the Euro against
the Japanese Yen and the US Dollar. Group cash position remains
strong at over Euros 9.3 million (USD 12.7 million) as of end of
December 2004. This cash level was maintained throughout 2004.
Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented:
"We are pleased with our 2004 preliminary figures. The significant
progression recorded on our Ablatherm(R) sales together with the
dramatic increase in the number of patients treated with HIFU
confirm the high growth opportunity of the HIFU with Ablatherm(R)
business. EDAP's current successful experience in developing and
controlling its lithotripsy sales and service business will pave
the way in setting-up the HIFU with Ablatherm(R) business model. We
look forward to reporting further on our 2004 results later in
March." EDAP TMS S.A. is the global leader in the development,
production, marketing and distribution of a portfolio of minimally
invasive medical devices primarily for the treatment of urological
diseases. The Company currently develops and markets Ablatherm(R)
for the minimally invasive treatment of localized prostate cancer,
using High Intensity Focused Ultrasound (HIFU), through its HIFU
Division; it is also developing this technology for the treatment
of certain other types of tumors. EDAP TMS S.A. also produces and
commercializes medical equipment for treatment of urinary tract
stones using Extra-corporeal Shockwave Lithotripsy (ESWL), via its
Urology Devices and Services (UDS) Division. For more information
on the Company, contact our Investor Relations Dept by phone at +33
(0)4 78 26 40 46 or please see the Company's web site at:
http://www.edap-tms.com/. This press release contains, in addition
to historical information, forward-looking statements that involve
risks and uncertainties. These include statements regarding the
Company's growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. Contact: Hugues de Bantel,
Philippe Chauveau or Blandine Confort +33 4 78 26 40 46 DATASOURCE:
EDAP TMS S.A. CONTACT: Hugues de Bantel, Philippe Chauveau or
Blandine Confort, all of EDAP TMS S.A., +33-4-78-26-40-46 Web site:
http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024